#United States #IDEAYA Biosciences #South San Francisco #darovasertib #Oncology Center

IDEAYA Biosciences Initiates New Drug Application for Darovasertib

IDEAYA Biosciences, Inc. has taken a significant step forward in the fight against metastatic uveal melanoma (mUM) by initiating the New Drug Application (NDA) submission for its investigational drug darovasertib. This application will be submitted under the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence Real-Time Oncology Review (RTOR) program, which aims to accelerate the review process for promising cancer therapies.

Background of Darovasertib

Darovasertib, in combination with crizotinib, targets patients with first-line (1L) HLAA2-negative mUM. Following the results from the Phase 2/3 OptimUM-02 trial, which demonstrated impressive outcomes, IDEAYA's management is optimistic about the drug's potential. The trial showed that the darovasertib combination significantly reduced the risk of disease progression by 58%. This was achieved with a statistically significant improvement in progression-free survival (PFS), extending to a median of 6.9 months compared to 3.1 months for those receiving the investigator's choice of treatment.

Positive Trial Results

On April 13th, IDEAYA reported the positive topline data from the OptimUM-02 trial, not only meeting its primary endpoint but also achieving notable secondary outcome metrics. An overall response rate (ORR) of 37.1% was observed in patients treated with the darovasertib combination, including five complete responses, which is significantly greater than the 5.8% response rate in the comparator arm. Importantly, the safety profile of the combination therapy was manageable, aligning with previously documented results and the known side effects associated with both drugs.

Collaboration with the FDA

IDEAYA's CEO, Yujiro S. Hata, expressed gratitude for the company's continuous partnership with the FDA, which was instrumental in gaining acceptance into the RTOR program. The CEO emphasized that this moment marks a pivotal achievement for IDEAYA, especially for those living with mUM, who currently have limited treatment options. Hata highlighted that the trial's results provide compelling evidence of the darovasertib combination's potential benefits, and the company aims to work closely with the FDA to expedite access for patients.

Upcoming Steps

The company plans to initiate the RTOR submission process, commencing with its first pre-submission in May. They anticipate finalizing the NDA filing in the second half of 2026. Full results from the OptimUM-02 trial are scheduled to be presented during a late-breaking oral presentation at the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois.

In addition to the ongoing trials for the darovasertib and crizotinib combination in HLAA2-negative mUM, IDEAYA is also evaluating darovasertib's efficacy in HLA*A2-positive mUM, and in the neoadjuvant and adjuvant settings for primary uveal melanoma.

About IDEAYA Biosciences

IDEAYA is dedicated to advancing precision medicine in oncology, focusing on the discovery and development of novel therapies tailored to unique genetic profiles of tumors. Their extensive pipeline includes innovative approaches leveraging small-molecule drug discovery coupled with bioinformatics and translational biomarker validation to develop targeted therapies. Through a commitment to science and patient-centric approaches, IDEAYA strives to produce the next generation of oncology treatments designed to improve patient outcomes.

Conclusion

As IDEAYA Biosciences moves forward with its NDA submission for darovasertib, the broader oncology community remains hopeful for advancements in treatment options for patients grappling with metastatic uveal melanoma. The collaborative efforts with the FDA and robust trial results put IDEAYA on a trajectory to make a meaningful difference in the lives of patients battling this aggressive cancer.